Search results for: 'rare ran'

This Frost RadarTM covers the year 2022. Frost & Sullivan defines 5G network infrastructure to include the following: • Radio access networks (RAN) • Transport networks • Core networks, which may include one or more edge networks The 5G network infrastructure market includes public networks run by communications service providers (C...

The global 5G network infrastructure market is significant, measuring in the tens of billions of dollars annually. In the past, the network infrastructure market for cellular networks had one primary customer type: communications service providers (CSPs). Today, CSPs still make up the largest portion of the market, but enterprises in many different...

The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...

The global CGT therapeutics market is transitioning from a niche, high-complexity segment into a mainstream, high-growth therapeutic class. Driven by scientific breakthroughs, accelerated regulatory pathways, and the entry of next-generation platforms—including in vivo CRISPR gene editing, allogeneic “off-the-shelf” cell therapies, and automated sm...

Fifth-generation (5G) technology represents a fundamental shift in communication network architectures and accelerates revenue potential through innovative services that 5G-enabled smartphones, tablets, laptops, and Internet of Things (IoT) devices facilitate. This breakthrough technology delivers a potent combination of network capabilities and fl...

This Frost & Sullivan market insight presents an overview of the artificial intelligence (AI) initiatives powering the next-generation business support system (BSS) initiatives in the global mobile communications market. It describes the various opportunities that generative AI (Gen AI) supports with the enhancement of existing BSS functions and pr...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping therapeutics, diagnostics, and drug delivery across infectious diseases, oncology, rare genetic disorders, autoimmune conditions, cardiovascular disease, pulmonary fibrosis, neurodegeneratio...

There have been increasing incidences of rare ophthalmic diseases (e.g., retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis) and prevalent diseases (e.g., age-related macular degeneration [AMD], geographic atrophy). While clinicians have used small molecules as the conventional therapeutic modality to manage these diseases, the urg...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) highlights recent advances in biological therapies such as RNA therapies, biosimilars, gene therapies and cell therapies for the management of diseases such as cancer, neurodegenerative disorders and rare diseases. The research also provides technological insigh...